
Zurletrectinib Receives Priority Review from NMPA for NTRK Gene Fusion+ Advanced Solid Tumors
The pan-TRK inhibitor zurletrectinib (ICP-723) has received priority review from China’s Center for Drug Evaluation of the National Medicinal Products Administration (NMPA) for the treatment of patients with advanced solid tumors harboring NTRK gene …